SuperworthInmune Bio EPS INMB
Diluted earnings per share by quarter and over the last twelve months, from 2018.
- Last 12 months, to Jun 30, 2026
- −$0.69
- Latest quarter, Q2 FY26
- −$0.05
- Fiscal year 2025
- −$1.92
Inmune Bio's earnings per share was −$0.69 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.05.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$1.92 | n/a |
| FY2024 | −$2.12 | n/a |
| FY2023 | −$1.67 | n/a |
| FY2022 | −$1.53 | n/a |
| FY2021 | −$1.85 | n/a |
| FY2020 | −$0.99 | n/a |
| FY2019 | −$0.74 | n/a |
| FY2018 | −$1.44 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.05 | n/a | −$0.69 | |
| Q1 FY26 | −$0.20 | n/a | −$1.69 | |
| Q4 FY25 | −$0.20 | n/a | −$1.92 | |
| Q3 FY25 | −$0.24 | n/a | −$2.13 | |
| Q2 FY25 | −$1.05 | n/a | −$2.49 | |
| Q1 FY25 | −$0.43 | n/a | −$1.94 | |
| Q4 FY24 | −$0.41 | n/a | −$2.12 | |
| Q3 FY24 | −$0.60 | n/a | −$2.18 | |
| Q2 FY24 | −$0.50 | n/a | −$2.06 | |
| Q1 FY24 | −$0.61 | n/a | −$1.92 | |
| Q4 FY23 | −$0.47 | n/a | −$1.67 | |
| Q3 FY23 | −$0.48 | n/a | −$1.53 |
Against its peers
Companies in Healthcare nearest Inmune Bio's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| INMBInmune Bio | −$0.69 | |
| NEPHNephros | $0.16 | +33% a year |
| ATNMActinium Pharmaceuticals | $0.36 | |
| APTAlpha Pro Tech | $0.41 | +24% a year |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| ICCCImmucell | $0.08 | −58% a year |
| KEQUKewaunee Scientific | $2.76 | −33% a year |
| PDEXPro DEX | $4.11 | +52% a year |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| Peer median | $0.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Inmune Bio
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.